Market Reports Archives

Reportlinker.com announces that a new market research report is available in its catalogue:

United States Anesthesia and Respiratory Devices Market Outlook to 2017 – Respiratory Devices, Respiratory Measurement Devices, Airway and Anesthesia Devices, Anesthesia Machines, Sleep Apnea Diagnostic Systems, Pain Management Devices and Others

The report provides key market data on the United States Anesthesia and Respiratory Devices market. The report provides value (USD million), volume (units) and average price (USD) data for each segment and sub-segment within eight market categories – Airway and Anesthesia Devices, Anesthesia Machines, Pain Management Devices, Regional Anesthesia Disposables, Respiratory Devices, Respiratory Disposables, Respiratory Measurement Devices and Sleep Apnea Diagnostic Systems. Read the rest of this entry

Reportlinker.com announced its new market research report “Global Sleep Apnea Diagnostic And Therapeutic Devices Industry ”

This report analyzes the worldwide markets for Sleep Apnea Diagnostic and Therapeutic Devices in US$ Million by the following Product Segments: Diagnostic Devices (Fixed PSG, Ambulatory PSG, & Others (include Screening Devices)), and Therapeutic Devices (CPAP, Bi-Level PAP, Auto PAP, & Facial Interfaces (Masks and Humidifiers)).

The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2007 through 2015. A seven-year historic analysis is also provided for these markets.

The report profiles 57 companies including many key and niche players worldwide such as Astro-Med Inc., Grass Technologies, Cadwell Laboratories, Inc., CareFusion Corporation, Compumedics Ltd., DeVilbiss Healthcare, Embla Systems, evo Medical Solutions, Inc., Fisher & Paykel Healthcare Limited, Itamar Medical Ltd., Invacare Corporation, Natus Medical Inc., Bio-Logic, Stellate Systems, Inc., Philips Healthcare, ResMed Inc., Teleflex Medical, Vital Signs Inc., and Weinmann Geräte für Medizin GmbH+CCo. KG. Market data and analytics are derived from primary and secondary research.

Reportlinker.com announced the release of a new market research report “Global  Sleep Apnea Diagnostic And Therapeutic Devices Industry“.    This report analyzes the worldwide markets for Sleep Apnea Diagnostic and Therapeutic Devices in US$ Million  by the following Product Segments: Diagnostic Devices (Fixed PSG, Ambulatory  PSG, & Others include Screening Devices), and Therapeutic Devices (CPAP,  Bi-Level PAP, Auto PAP, & Facial Interfaces ,Masks and Humidifiers).

The  report provides separate comprehensive analytics for the US, Japan, Europe, and  Rest of World. Annual estimates and forecasts are provided for the period 2007  through 2015. A seven-year historic analysis is also provided for these markets. Read the rest of this entry

  •  The global respiratory  devices market is set to reach $7.1 billion by 2017
  •  The PAP device market is the largest segment in the global respiratory devices market and accounted for 58% of the market
  •  The US market for respiratory devices was valued at $2.4 billion in 2010

The global respiratory devices market is forecast to grow from $4.5 billion in 2010 to $7.1 billion by 2017, according to a new report available on companiesandmarkets.com. Read the rest of this entry

US medical giant ResMed buys UCD spin-out in all-cash deal

San Diego-headquartered medical device manufacturer ResMed has acquired UCD spin-out BiancaMed in an all-cash deal. Original investors including DFJ ePlanet Capital and Enterprise Ireland are believed to receive a significant premium on their €11m investment in the company.

BiancaMed is one of an emerging generation of young Irish medical device companies who are developing breakthrough technologies. It has developed a contactless, accurate device to measure sleep and breathing and combat deaths arising from the sleep disorder sleep apnea. Read the rest of this entry

SleepApneaDisorder/[Press Release i]/ June 27, 2011/ Safeguard Scientifics, Inc. (NYSE: SFE), a holding company that builds value in growth-stage life sciences and technology companies, today announced that it led a $35 million Series D financing for Baltimore, MD-based NovaSom, a diagnostics company enabling home diagnosis and treatment of obstructive sleep apnea (OSA). Safeguard provided $20 million of financing; the additional $15 million was provided by existing investors, including TPG Biotechnology II Fund and Quaker BioVentures, among others. Proceeds from the financing will be used to fund growth, expand its leadership position in payer and provider markets, and develop additional innovations within the company’s proprietary NovaSom® diagnostic medical device and cloud-based MediTrack® Patient Management Portals. Read the rest of this entry

Watermark Medical, Inc. (“Watermark”), the leader in Health Information  Technology for managing chronic diseases, has aligned with the American Academy  of Sleep Medicine (AASM) in expanding requirements for board certified doctors  on their end to end cloud based platform for diagnosing Obstructive Sleep Apnea  (OSA).In addition, Watermark announced today the commercial availability of WM  Secure Sleep Study™ (WM S3). The WM S3 integrates with the ARES™ home sleep test to provide “chain of custody” (CoC) validation to support occupational testing  of commercial truck drivers in the comfort of their home or cab. The  transportation industry’s growing recognition of the liability, cost and health  risk resulting from untreated OSA has caused a call to action to implement more  robust screening and testing protocols. Read the rest of this entry

SleepApneaDisorder/[ Press Release ]/ Minneapolis, USA/  – SLEEP 2011 will bring current research and clinical practices to the forefront for sleep specialists from around the world this week at the Associated Professional Sleep Societies, LLC annual meeting. And Royal Philips Electronics (NYSE: PHG, AEX: PHI) will demonstrate the latest advances in sleep with the premiere of “Pathway to Compliance.” The interactive showcase features the latest breakthroughs for diagnosing, treating and managing the entire spectrum of sleep-disordered breathing patients and guides them on their journey to better sleep. “Tremendous strides have been made to deepen our understanding of sleep,” says John Frank, Sr. Vice President, General Manager, Sleep and Respiratory Care, Philips Home Healthcare Solutions. “There is growing evidence of co-morbidities such as diabetes, obesity, and cardiovascular disease. As allies in better sleep and breathing, we are committed to meeting these challenges with intelligent solutions. With “Pathway to Compliance,” we will show how new advances are making the future of sleep and therapy compliance a reality for patients and clinicians.” Read the rest of this entry

The full year results for Fisher & Paykel Healthcare are due on Wednesday and those of Fisher & Paykel Appliances will be released on Friday.

Analysts will be closely watching Fisher and Paykel Healthcare’s sleep apnea range, and what impact the high New Zealand dollar could have on the business during the year ahead. The medical equipment manufacturer’s guidance for the full year is for a profit of between $60 and $63 million.

But Forsyth Barr senior analyst Guy Halwright says this may be pushed slightly higher due to the New Zealand dollar over the past six months.

He says the sleep apnea market has been slower than previously, but it’s unclear whether this is simply a lingering effect of the economic crisis and the slow American economy.He says the high New Zealand currency is the main problem facing Fisher & Paykel. Read the rest of this entry

Graymark Healthcare, Inc. the nation’s second largest provider of diagnostic sleep services and an innovator in comprehensive care for obstructive sleep apnea (OSA), entered into subscription agreements with insiders and existing accredited investors to sell $3 million of newly issued shares of its common stock and warrants in a private placement.

Under the terms of the transaction, Graymark will sell 5,172,411 million shares for $0.58 per share, a 29% premium to Friday’s consolidated closing bid price of $0.45 per share. The purchasers will also receive warrants to purchase up to an aggregate of approximately 5,172,411 million shares of common stock at an exercise price of $0.45 per share. The warrants may be exercised beginning 6 months after the closing date and will expire in 3 years. The closing of the transaction is expected to take place on or about May 6, 2011, subject to the satisfaction of customary closing conditions.

No investment banking or advisory fees were paid by the company.The company intends to use the proceeds of this private placement to pay down its short-term debt obligations with Arvest Bank as well as for general corporate purposes.

Related Posts with Thumbnails